Startups & Funding

Isomorphic Labs Raises $5B as AI Drug Design Faces Trial Test

Isomorphic Labs raised $5 billion to expand IsoDDE and clinical infrastructure. The Series C follows two earlier rounds, while human trial results remain the decisive test.

Isomorphic Labs Raises $5B Series C to Advance AI Drug Design
Isomorphic Labs Raises $5B Series C to Advance AI Drug Designjarmoluk / pixabay
By James Calloway5 min read

Why it matters

  • Isomorphic Labs announced a $5 billion Series C on November 17, 2026; Greenoaks and Sequoia Capital co-led the oversubscribed round.
  • Thrive Capital led a $600 million first external round on March 31, 2025, and a $2.1 billion Series B on May 12, 2026.
  • Alphabet invested again in Series C; Andreessen Horowitz joined, and every existing investor returned.
  • IsoDDE designs drug-like molecules; Isomorphic reports positive preclinical outcomes in owned oncology and immunology programs and partnered work.
  • Novartis started three small-molecule targets in January 2024 and added up to three research programs in February 2025.

By James Calloway

Isomorphic Labs announced $5 billion in Series C funding on November 17, 2026; Greenoaks and Sequoia Capital co-led the oversubscribed round. Isomorphic says the money will expand IsoDDE and clinical infrastructure, but its announcement presents preclinical findings rather than human-trial evidence.

That distinction sets the stakes for investors and pharmaceutical partners. Isomorphic reports positive preclinical outcomes from wholly owned and partnered programs, meaning laboratory-stage results before human testing. The central test, as the company frames it, is whether that progress becomes clinical evidence when candidates enter human trials.

The announcement names no therapeutic candidate, trial sponsor, trial start date or endpoint (a prespecified outcome measure). It therefore establishes a firmer fact about financing than about clinical validation.

What does the $5 billion fund?

Isomorphic says the proceeds will fund five connected areas. The company presents them as a path from expanded biological models to patient testing.

  • Further development of IsoDDE, the proprietary drug-design engine.
  • Expansion into new areas of biology.
  • Global infrastructure for AI-led bioengineering (engineering biological systems with AI).
  • A partner ecosystem to study mechanisms that drive disease.
  • Translational and clinical-development infrastructure (the path from laboratory research to patient testing) and support for candidates approaching trials.

The release assigns no dollar amount to any category. The $5 billion may support several programs at once, but Isomorphic provides no milestone schedule, candidate names or trial timetable.

Founder and CEO Demis Hassabis said in the funding release: “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”

The quote sets three objectives: foundational biology models, deeper systemic disease understanding and first therapeutic programs moving toward trials. It does not define success measures, identify those programs or specify a testing schedule. Nor does the announcement publish a public IsoDDE benchmark.

Takeaway: The round buys models and infrastructure, not proof that the drug designs work in people.

How quickly did Isomorphic's funding grow?

Isomorphic's latest round follows two financings led by Thrive Capital, according to its announcement. Across the three disclosed external rounds, round sizes rose from $600 million to $2.1 billion and then $5 billion.

  • $600 million first external round, announced March 31, 2025: Thrive Capital led the financing, with GV participating and Alphabet providing follow-on capital.
  • $2.1 billion Series B, announced May 12, 2026: Thrive Capital led the round, while Alphabet and GV participated alongside new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund.

In the Series C, Greenoaks and Sequoia Capital served as co-leaders. Alphabet made another significant investment, and Andreessen Horowitz joined with several other unnamed investors. Every existing investor returned: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

Isomorphic's announcement does not disclose its valuation, ownership percentages, investor commitments or commercial terms. The sequence shows how quickly the company has assembled funding, but it does not establish whether that capital has produced a clinical asset.

Takeaway: Isomorphic has raised increasingly large rounds, though the money still precedes the evidence investors need.

What is IsoDDE, and what evidence supports it?

Isomorphic describes IsoDDE as a collection of AI simulation models (software-based models) built to handle different therapeutic areas and types of drugs. The platform searches chemical space, or the universe of possible molecular structures, to design and refine molecules with drug-like properties.

Proprietary agents within the platform navigate and reason through complex biology, according to Isomorphic. The company does not publish a model version, benchmark suite or independent evaluation of that biological-analysis system.

Isomorphic reports positive preclinical outcomes from wholly owned oncology (cancer-treatment) and immunology (immune-system treatment) programs and from partnered work. It presents those findings as the basis for moving toward clinical trials.

The announcement gives no molecule names, experimental methods, quantitative effect sizes, comparisons with other design methods or independent replication. Readers therefore have the company's characterization, but not the underlying evidence needed to assess how general or reproducible the preclinical gains might be.

Takeaway: IsoDDE has company-reported preclinical support, but the release provides no benchmarks or candidate-level data.

Which partners are building the pipeline?

Isomorphic's external portfolio includes Novartis, Eli Lilly and Johnson & Johnson, according to the announcement. The collaboration structures differ, and Isomorphic's release supplies no compound-level results for any partner.

Novartis began working with Isomorphic in January 2024 on small molecules against three challenging targets. The companies expanded that work in February 2025, adding up to three additional research programs.

The Eli Lilly collaboration focuses on small-molecule therapeutics against undisclosed targets. The multi-target Johnson & Johnson collaboration spans both small molecules, or conventional chemical drugs, and biologics, or biologically derived therapeutics.

Together with Isomorphic's wholly owned oncology and immunology work, the partnerships create a portfolio spanning several disease areas and drug formats. The release does not say which programs remain preclinical, which have reached candidate status or how responsibilities and economics divide among the partners.

Takeaway: Partnerships widen Isomorphic's portfolio, but the announcement still offers no candidate-level clinical data.

What has to happen before the models become drugs?

The Series C gives Isomorphic resources to develop its models and clinical-development infrastructure together, according to the company. That combination matters because stronger models have clinical value only if proposed treatments move from laboratory studies into human testing and produce evidence.

The next evidence would be candidate names, trial designs, dates and results. Isomorphic's announcement provides none of those details and ends at the threshold of human testing. It also gives no data showing how many IsoDDE-designed molecules have entered trials or whether any produced favorable outcomes.

For pharmaceutical partners, the near-term benefit is more discovery capacity across small molecules and biologics. For investors, the $5 billion remains a commitment to preclinical claims, model development and a clinical pipeline whose members the announcement does not name. The next credible checkpoints are disclosed programs, trial activity and human evidence.

Takeaway: Until named trials and human results appear, the financing measures confidence in Isomorphic's platform more clearly than clinical validation.

Source: unite.ai

Share this article:

More from James Calloway

James Calloway

Show full bio

News editor covering people, launches and day-to-day practice in artificial intelligence and machine learning at AI In Context.

722 articles

Related articles

  1. Isomorphic Labs raises $5B to push AI-designed drugs into trials
  2. Isomorphic Labs raises $5 billion, its second mega-round in six months
  3. Orakl Oncology raises $34 million to scale AI cancer predictions
  4. TestDynamics Raises $9 Million to Evaluate Medical Imaging AI
  5. Every Cure, OpenEvidence launch AI drug-repurposing partnership

« Previous articleNext article »